Abstract:Introduction: A group of SARS-CoV-2 infected individuals present lingering symptoms, defined as long COVID (LC), that may last months or years post the onset of acute disease. A portion of LC patients have symptoms similar to myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), which results in a substantial reduction in their quality of life. A better understanding of the pathophysiology of LC, in particular, ME/CFS is urgently needed. Methods: We identified and studied metabolites and soluble biomarkers in plasma from LC individuals mainly exhibiting ME/CFS compared to age-sex-matched recovered individuals (R) without LC, acute COVID-19 patients (A), and to SARS-CoV-2 unexposed healthy individuals (HC). Results: Through these analyses, we identified alterations in several metabolomic pathways in LC vs other groups. Plasma metabolomics analysis showed that LC differed from the R and HC groups. Of note, the R group also exhibited a different metabolomic profile than HC. Moreover, we observed a significant elevation in the plasma pro-inflammatory biomarkers (e.g. IL-1α, IL-6, TNF-α, Flt-1, and sCD14) but the reduction in ATP in LC patients. Our results demonstrate that LC patients exhibit persistent metabolomic abnormalities 12 months after the acute COVID-19 disease. Of note, such metabolomic alterations can be observed in the R group 12 months after the acute disease. Hence, the metabolomic recovery period for infected individuals with SARS-CoV-2 might be long-lasting. In particular, we found a significant reduction in sarcosine and serine concentrations in LC patients, which was inversely correlated with depression, anxiety, and cognitive dysfunction scores. Conclusion: Our study findings provide a comprehensive metabolomic knowledge base and other soluble biomarkers for a better understanding of the pathophysiology of LC and suggests sarcosine and serine supplementations might have potential therapeutic implications in LC patients. Finally, our study reveals that LC disproportionally affects females more than males, as evidenced by nearly 70% of our LC patients being female.

Long-COVID-19 autonomic dysfunction: An integrated view in the framework of inflammaging

From aging to long COVID: exploring the convergence of immunosenescence, inflammaging, and autoimmunity

Inflammaging, immunosenescence, and cardiovascular aging: insights into long COVID implications

Autonomic nervous system imbalance during aging contributes to impair endogenous anti-inflammaging strategies

Autonomic Imbalance and Elevated Inflammatory Cytokines in Long COVID: A Cross-Sectional Study

Connecting dots of long COVID-19 pathogenesis: a vagus nerve- hypothalamic-pituitary- adrenal-mitochondrial axis dysfunction

Long-COVID autonomic syndrome in working age and work ability impairment

Inflammaging and immunosenescence in the post‐COVID era: small molecules, big challenges

Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics

A review of cytokine-based pathophysiology of Long COVID symptoms

The Central Role of Low-Grade Inflammation and Multisystem Involvement

Systems analysis of innate and adaptive immunity in Long COVID

Reduced autonomic function in patients with long-COVID-19 syndrome is mediated by cardiorespiratory fitness

Revealing the Hidden Impacts: Insights into Biological Aging and Long-Term Effects in Pauci- and Asymptomatic COVID-19 Healthcare Workers

Inflammatory mediators and lung function in older COVID-19 survivors.

Long COVID and pituitary dysfunctions: a bidirectional relationship?

Gut Microbiota and Mitochondria: Health and Pathophysiological Aspects of Long COVID

Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome

Heart rate variability and autonomic nervous system imbalance: Potential biomarkers and detectable hallmarks of aging and inflammaging

Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2

Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2